8-K: 3D Systems Announces Preliminary Q3 2024 Revenue, Cites Macroeconomic Headwinds and Transaction Delays

Sentiment:

Preliminary Earnings Announcement


3D Systems reported preliminary third-quarter revenue of approximately $113 million, a decrease from the previous year, and announced a delay in filing its quarterly report due to a required goodwill valuation.

Delay expectedThe company is delaying the filing of its Quarterly Report on Form 10-Q due to the need for an interim valuation of goodwill and long-lived assets.
Worse than expectedThe company's revenue decreased by $10.9 million compared to the same quarter last year, indicating worse than expected performance.

Summary

  • 3D Systems announced preliminary revenue for the third quarter of 2024 to be approximately $113 million.
  • This represents a decrease of $10.9 million compared to the third quarter of 2023, which had revenue of $123.8 million.
  • The revenue decline was primarily due to macroeconomic factors impacting hardware system sales and customer delays in closing key transactions.
  • Material revenue grew by 10% year-over-year and 9% sequentially, indicating strong performance in consumables.
  • The company experienced delays in closing certain key transactions, which were not fully completed until early in the fourth quarter of 2024.
  • 3D Systems is delaying the filing of its Quarterly Report on Form 10-Q due to the need for an interim valuation of goodwill and long-lived assets.
  • The company expects to release its full third-quarter 2024 financial results the week of November 25, 2024.

Sentiment

Score: 5

Explanation: The document presents mixed signals with strong material growth and positive developments in healthcare, but is offset by a revenue decline, transaction delays, and a delay in filing the 10-Q. The sentiment is neutral to slightly negative.

Positives

  • Material revenue showed strong growth, increasing by 10% year-over-year and 9% sequentially.
  • The Personalized Healthcare business experienced nearly 20% growth compared to the same quarter last year.
  • The company secured FDA clearances for new dental and orthopedic products, which are expected to drive future growth.
  • 3D Systems is maintaining its investment in R&D and application development.
  • The company is executing restructuring plans to improve operational efficiency and reduce costs.

Negatives

  • Total revenue decreased by $10.9 million compared to the third quarter of 2023.
  • Hardware system sales were negatively impacted by macroeconomic pressures.
  • Customer delays in closing key transactions affected third-quarter revenue.
  • The company is delaying the filing of its Quarterly Report on Form 10-Q.

Risks

  • Macroeconomic pressures continue to negatively impact hardware system sales.
  • Customer delays in closing transactions can affect revenue recognition.
  • The need for an interim valuation of goodwill and long-lived assets indicates potential financial concerns.
  • Market volatility and stock performance can trigger additional valuation requirements.

Future Outlook

The company anticipates future revenue growth as the economy normalizes, supported by product innovation and regulatory approvals. They expect to capitalize on pent-up demand in the near future.

Management Comments

  • Dr. Jeffrey Graves, president and CEO, stated that the company is navigating a challenging operating environment, particularly related to new hardware system sales.
  • Dr. Graves noted that the installed base remains robust, driving strong materials utilization.
  • Dr. Graves mentioned that the company is making considerable progress across its technology roadmap.
  • Dr. Graves highlighted the company's focus on innovation and attainment of critical scale in key markets.
  • Dr. Graves stated that the company is executing against restructuring plans to drive operational efficiency and cost reduction.

Industry Context

The announcement reflects the broader challenges in the additive manufacturing industry, particularly in hardware sales, due to macroeconomic pressures. However, the growth in materials revenue and focus on key markets like healthcare aligns with industry trends towards specialized applications.

Comparison to Industry Standards

  • While 3D Systems experienced a decline in overall revenue, the 10% year-over-year growth in materials revenue is a positive sign, indicating a strong recurring revenue stream, similar to companies like Stratasys which also focus on materials.
  • The delay in closing key transactions is a common issue in the capital equipment sector, impacting companies like Desktop Metal, which have also faced challenges in converting sales pipelines into revenue.
  • The focus on healthcare applications and FDA clearances is a strategic move, similar to companies like Align Technology in the dental space, which have seen significant growth due to regulatory approvals and market adoption.
  • The need for a goodwill valuation is a concern, and is not uncommon in the current economic climate, with other companies in the tech sector also facing similar challenges.

Stakeholder Impact

  • Shareholders may be concerned about the revenue decline and delay in filing the 10-Q.
  • Employees may be affected by the ongoing restructuring plans.
  • Customers may experience delays in transactions and product delivery.
  • Suppliers may be impacted by changes in the company's operations and spending.

Next Steps

  • The company will release its full third-quarter 2024 financial results the week of November 25, 2024.
  • The company will file a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission.

Key Dates

DateDescription
September 30, 2024End of the third quarter for which financial results are being reported.
November 13, 2024Date of the press release announcing preliminary Q3 2024 results and delay of 10-Q filing.
Week of November 25, 2024Expected release date for the full third-quarter 2024 financial results.

Keywords

3D Printing, Additive Manufacturing, Revenue, Financial Results, Materials, Healthcare, Dental, Orthopedic, FDA Clearance, Form 10-Q, Goodwill Valuation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.